Morita, Y.; Sugimoto, R.; Kurokawa, M.; Tanaka, Y.; Senju, T.; Ichimaru, T.; Lee, L.; Niina, Y.; Hisano, T.; Furukawa, M.;
et al. Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab. Cancers 2025, 17, 3971.
https://doi.org/10.3390/cancers17243971
AMA Style
Morita Y, Sugimoto R, Kurokawa M, Tanaka Y, Senju T, Ichimaru T, Lee L, Niina Y, Hisano T, Furukawa M,
et al. Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab. Cancers. 2025; 17(24):3971.
https://doi.org/10.3390/cancers17243971
Chicago/Turabian Style
Morita, Yusuke, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa,
and et al. 2025. "Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab" Cancers 17, no. 24: 3971.
https://doi.org/10.3390/cancers17243971
APA Style
Morita, Y., Sugimoto, R., Kurokawa, M., Tanaka, Y., Senju, T., Ichimaru, T., Lee, L., Niina, Y., Hisano, T., Furukawa, M., Sugimachi, K., & Tanaka, M.
(2025). Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab. Cancers, 17(24), 3971.
https://doi.org/10.3390/cancers17243971
